AI Article Synopsis

  • The MiniMed Continuous Glucose Monitoring System (CGMS) measures glucose in the interstitial fluid and is calibrated daily using fingerstick blood samples.
  • The study investigated how changes in plasma glucose and insulin levels affect the performance of the CGMS in healthy subjects during controlled glucose levels.
  • Results showed that while hyperinsulinemia can create some differences between plasma and sensor glucose, proper calibration allows the CGMS to accurately reflect acute changes in glucose levels.

Article Abstract

Objective: The MiniMed Continuous Glucose Monitoring System (CGMS) measures subcutaneous interstitial glucose levels that are calibrated against three or more fingerstick glucose levels daily. The objective of the present study was to examine whether the relationship between plasma and interstitial fluid glucose is altered by changes in plasma glucose and insulin levels and how such alterations might influence CGMS performance.

Research Design And Methods: Arterialized plasma glucose, sensor glucose, and interstitial fluid glucose were measured by microdialysis in 11 healthy subjects during a 1.0 mU. kg(-1). min(-1) stepped euglycemic-hypoglycemic-hyperglycemic (plasma glucose approximately 5, 3.1, and 8.6 mmol/l, respectively) insulin clamp that raised plasma insulin to approximately 360-390 pmol/l.

Results: When the CGMS was calibrated versus plasma glucose levels before insulin infusion, basal sensor and plasma glucose were similar (5.0 +/- 0.3 vs. 5.2 +/- 0.3 mmol/l, respectively); dialysate glucose was 3.3 +/- 0.9 mmol/l. During the hyperinsulinemic-euglycemia study (plasma glucose 4.9 +/- 0.3 mmol/l), dialysate glucose fell by 30-35%, accompanied by a significant reduction in sensor glucose (to 3.7 +/- 0.6 mmol/l; P < 0.001 vs. plasma). Subsequently, sensor levels remained lower than plasma values during mild hypoglycemia (2.5 +/- 0.6 vs. 3.1 +/- 0.3 mmol/l; P < 0.01) and during recovery from hypoglycemia (7.3 +/- 1.2 vs. 8.6 +/- 0.6; P < 0.01). However, when the CGMS was calibrated against plasma glucose levels before and during each step of the clamp, sensor glucose levels increased throughout the study and did not differ from plasma glucose values during hypoglycemia.

Conclusions: Although hyperinsulinemia may contribute to modest discrepancies between plasma and sensor glucose levels, the CGMS is able to accurately track acute changes in plasma glucose when calibrated across a range of plasma glucose and insulin levels.

Download full-text PDF

Source
http://dx.doi.org/10.2337/diacare.25.5.889DOI Listing

Publication Analysis

Top Keywords

plasma glucose
44
glucose levels
28
glucose
22
sensor glucose
20
+/- mmol/l
20
plasma
16
glucose +/-
16
+/- +/-
12
levels
10
+/-
9

Similar Publications

Background: Obesity is a chronic disease associated with other associated medical problems, including atherogenic dyslipidemia. Metabolic bariatric surgery (MBS) has been shown to reduce long-term cardiovascular risk (CVR). Anti-ApoA-1 antibodies (AAA1) are independently associated with cardiovascular disease, which remains a major cause of death in individuals with obesity.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Background: While disease-modifying treatments that reduce Aβ have been recently approved by the FDA, the identification of novel therapeutic targets and strategies that target underlying mechanisms to delay the AD development are still needed. Abnormal brain energy homeostasis and mitochondria dysfunction are observed early in AD. Therefore, the development of treatments to restore these defects could be beneficial.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Huashan Hospital, Fudan University, Shanghai, China.

Background: Identifying circulating metabolites associated with dementia, cognition, and brain volume may improve the understanding of dementia pathogenesis and provide novel insights for preventive and therapeutic interventions.

Method: This cohort study included a total of 87,885 participants (median follow-up 9.1 years, 54% female) without dementia at baseline from the UK Biobank.

View Article and Find Full Text PDF

Background: The global burden of metabolic diseases is increasing, but estimates of their impact on primary liver cancer are uncertain. We aimed to assess the global burden of primary liver cancer attributable to metabolic risk factors, including high body mass index (BMI) and high fasting plasma glucose (FPG) levels, between 1990 and 2021.

Methods: The total number and age-standardized rates of deaths and disability-adjusted life years (DALYs) from primary liver cancer attributable to each metabolic risk factor were extracted from the Global Burden of Disease Study 1990-2021.

View Article and Find Full Text PDF

Background: We aimed to contribute to the literature by exploring the possible relationship of PV with erectile dysfunction (ED), as in atherosclerosis-based vascular diseases.

Methods: Between October 2021 and December 2022, 99 patients who applied to the urology polyclinic with a complaint of ED were included in the study (Group 1). Fifty-two patients who applied with a complaint other than ED constituted the control group (Group 2).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!